NCT02268253 2025-01-06Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)Stemline Therapeutics, Inc.Phase 1/2 Completed82 enrolled 15 charts